Related Experiment Videos
Fomivirsen.
1ISTA Pharmaceuticals (previously Isis Pharmaceuticals, Inc.), Irvine, California, USA.
Drugs of Today (Barcelona, Spain : 1998)
|May 28, 2003
Summary
Fomivirsen effectively treats cytomegalovirus (CMV) retinitis in AIDS patients. This novel antisense drug, administered locally, shows minimal systemic absorption and manageable ocular side effects, preventing blindness.
Area of Science:
- Ophthalmology
- Virology
- Pharmacology
Background:
- Cytomegalovirus (CMV) retinitis poses a significant risk of blindness in individuals with acquired immune deficiency syndrome (AIDS).
- Existing therapies for CMV retinitis may be ineffective in certain patient populations, necessitating novel treatment approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of fomivirsen, a novel antisense drug, for treating CMV retinitis in patients with AIDS.
- To assess the systemic absorption and potential adverse events associated with intravitreal fomivirsen administration.
Main Methods:
- Clinical trials were conducted to assess fomivirsen's effectiveness in patients with newly diagnosed or relapsed CMV retinitis.
- Systemic absorption and local ocular effects were monitored following intravitreal administration of fomivirsen at specified dosages.
Main Results:
- Fomivirsen demonstrated effective treatment for peripheral CMV retinitis in both newly diagnosed and relapsed cases unresponsive to conventional therapy.
- Intravitreal fomivirsen administration resulted in minimal measurable systemic absorption of the drug or its metabolites.
- The primary adverse events were mild to moderate, transient local ocular effects manageable with topical medications.
Conclusions:
- Fomivirsen is an effective therapeutic option for CMV retinitis in AIDS patients, particularly those with treatment-resistant or relapsed disease.
- Local intravitreal administration of fomivirsen offers a favorable safety profile with minimal systemic exposure and manageable ocular side effects.